251 related articles for article (PubMed ID: 33119175)
1. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.
Seymour EK; Ruterbusch JJ; Winn AN; George JA; Beebe-Dimmer JL; Schiffer CA
Cancer; 2021 Jan; 127(1):93-102. PubMed ID: 33119175
[TBL] [Abstract][Full Text] [Related]
2. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
Winn AN; Keating NL; Dusetzina SB
J Clin Oncol; 2016 Dec; 34(36):4323-4328. PubMed ID: 27998234
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine Kinase Inhibitors Initiation, Cost Sharing, and Health Care Utilization in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
Phuar HL; Begley CE; Chan W; Krause TM
J Manag Care Spec Pharm; 2019 Oct; 25(10):1140-1150. PubMed ID: 31556823
[TBL] [Abstract][Full Text] [Related]
4. Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.
Shen C; Zhao B; Liu L; Shih YT
Cancer; 2018 Jan; 124(2):364-373. PubMed ID: 28976559
[TBL] [Abstract][Full Text] [Related]
5. Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients.
Rivera DR; Enewold L; Barrett MJ; Banegas MP; Filipski KK; Freedman AN; Lam CK; Mariotto A
J Manag Care Spec Pharm; 2020 Dec; 26(12):1494-1504. PubMed ID: 33251998
[No Abstract] [Full Text] [Related]
6. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
[TBL] [Abstract][Full Text] [Related]
7. Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia.
Kenzik KM; Bhatia R; Williams GR; Bhatia S
Cancer; 2019 Aug; 125(15):2570-2578. PubMed ID: 30973642
[TBL] [Abstract][Full Text] [Related]
8. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
Latremouille-Viau D; Guerin A; Gagnon-Sanschagrin P; Dea K; Cohen BG; Joseph GJ
J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373
[TBL] [Abstract][Full Text] [Related]
9. Coverage and use of cancer therapies in the treatment of chronic myeloid leukemia.
Darkow T; Maclean R; Joyce GF; Goldman D; Lakdawalla DN
Am J Manag Care; 2012 Nov; 18(11 Suppl):S272-8. PubMed ID: 23327459
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
Phuar HL; Begley CE; Chan W; Krause TM
Am J Clin Oncol; 2020 Jul; 43(7):517-525. PubMed ID: 32304434
[TBL] [Abstract][Full Text] [Related]
11. Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data.
Lang K; McGarry LJ; Huang H; Dorer D; Kaufman E; Knopf K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):275-285.e1. PubMed ID: 27013180
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy.
Smith BD; Liu J; Latremouille-Viau D; Guerin A; Fernandez D; Chen L
Curr Med Res Opin; 2016 May; 32(5):817-27. PubMed ID: 26743563
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs.
Ward MA; Fang G; Richards KL; Walko CM; Earnshaw SR; Happe LE; Blalock SJ
Curr Med Res Opin; 2015 Feb; 31(2):289-97. PubMed ID: 25420131
[TBL] [Abstract][Full Text] [Related]
14. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia.
Doshi JA; Li P; Huo H; Pettit AR; Kumar R; Weiss BM; Huntington SF
Am J Manag Care; 2016 Mar; 22(4 Suppl):s78-86. PubMed ID: 27270157
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States.
Latremouille-Viau D; Guerin A; Nitulescu R; Gagnon PS; Joseph GJ; Chen L
J Med Econ; 2017 Jan; 20(1):63-71. PubMed ID: 27603674
[TBL] [Abstract][Full Text] [Related]
16. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America.
Karalexi MA; Baka M; Ryzhov A; Zborovskaya A; Dimitrova N; Zivkovic S; Eser S; Antunes L; Sekerija M; Zagar T; Bastos J; Demetriou A; Agius D; Florea M; Coza D; Polychronopoulou S; Stiakaki E; Moschovi M; Hatzipantelis E; Kourti M; Graphakos S; Pombo-de-Oliveira MS; Adami HO; Petridou ET
Eur J Cancer; 2016 Nov; 67():183-190. PubMed ID: 27677054
[TBL] [Abstract][Full Text] [Related]
17. Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia: An Analysis of SEER-Medicare Data From 1995 to 2007.
Lin PJ; Winn AN; Parsons SK; Neumann PJ; Weiss ES; Cohen JT
Med Care; 2016 Apr; 54(4):380-5. PubMed ID: 26759984
[TBL] [Abstract][Full Text] [Related]
18. Economic Burden of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia.
Knopf KB; Divino V; McGarry L; Chen YJ; Pokras S; Munakata J; Taylor C; Ng D; Nieset C; Huang H
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e163-71. PubMed ID: 26411541
[TBL] [Abstract][Full Text] [Related]
19. Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.
Lin J; Makenbaeva D; Lingohr-Smith M; Bilmes R
J Med Econ; 2017 Jul; 20(7):687-691. PubMed ID: 28287043
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
